(Bloomberg) -- Sales of Valeant Pharmaceuticals International Inc.'s female libido pill Addyi have been falling since the company was said to cut the drug's sales force. There have been concerns about the treatment's effectiveness, its side effects -- including fainting -- as well as its price and coverage by health insurers since sales began in October. Valeant believes Addyi has strong potential and is building a new internal sales force, Tracy Valorie, general manager of women's health at the company, said in an e-mail.
(Updates with Valeant comment.)
To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net. To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, John Lauerman
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
